Top 30 Vaccine & Immunotherapy Developers 2026

This report forms part of The Economy Rankings Healthcare Ranking series, which evaluates hospitals, medical institutions, pharmaceutical organizations, medical technology companies, diagnostics providers, laboratories, precision medicine platforms, and healthcare systems across global healthcare markets.

Vaccine and immunotherapy developers occupy a central position within modern healthcare by using the immune system to prevent, control, or treat disease. Their work spans infectious disease vaccines, cancer immunotherapies, therapeutic cancer vaccines, monoclonal antibodies, immune checkpoint inhibitors, bispecific antibodies, mRNA platforms, cell-based immunotherapies, adjuvant technologies, and immune-modulating therapies.

Unlike conventional pharmaceutical categories based primarily on chemical small molecules, vaccine and immunotherapy developers depend on deep biological understanding of immune recognition, antigen presentation, antibody response, T-cell activation, immune memory, tumor microenvironments, inflammatory signaling, and immune tolerance. Their institutional relevance is determined not only by product revenue, but also by scientific platform strength, manufacturing capability, clinical evidence, public health role, and long-term therapeutic innovation.

The sector has changed significantly since the COVID-19 pandemic. mRNA vaccines demonstrated the speed and scalability of new vaccine platforms, while traditional vaccine leaders such as GSK, Sanofi, Merck, and Pfizer continue to dominate major commercial segments. At the same time, immunotherapy remains one of the most important areas in oncology, with companies such as Merck, Bristol Myers Squibb, Roche, AstraZeneca, Regeneron, Genmab, BioNTech, and Moderna shaping the future of immune-based cancer treatment.

This ranking identifies vaccine and immunotherapy developers whose platforms demonstrate sustained relevance across infectious disease prevention, cancer immunotherapy, immune modulation, biologics, mRNA, antibody engineering, public health supply, and therapeutic innovation. Rather than focusing only on vaccine dose volume or oncology revenue, the objective is to recognize organizations that remain structurally important in immune-based medicine.

Market Overview

The vaccine and immunotherapy market consists of two overlapping but distinct segments. The vaccine segment includes preventive vaccines for infectious diseases such as influenza, COVID-19, pneumococcal disease, HPV, shingles, RSV, meningococcal disease, hepatitis, and childhood immunization schedules. The immunotherapy segment includes immune checkpoint inhibitors, monoclonal antibodies, bispecific antibodies, cancer vaccines, cell therapies, immune modulators, and therapeutic platforms designed to harness or modify immune responses.

The vaccine market remains highly concentrated by financial value, while large developing-country manufacturers dominate dose volume. The WHO’s 2025 Global Vaccine Market Report notes that more than 84% of total vaccine financial value was concentrated in the top 10 manufacturers in 2024, while Serum Institute of India was the dominant manufacturer by volume and accounted for roughly twice the volume of the next-largest manufacturer.

Traditional vaccine leaders remain central. Market analyses continue to identify Merck, GSK, Sanofi, Pfizer, Moderna, AstraZeneca, Novavax, Johnson & Johnson, and Serum Institute of India among major vaccine manufacturers, with Pfizer, Merck, GSK, and Sanofi historically holding strong positions in high-value vaccine markets.

In immunotherapy, oncology remains the most commercially important segment. Merck’s Keytruda, Bristol Myers Squibb’s Opdivo and Yervoy, Roche’s Tecentriq, AstraZeneca’s Imfinzi, Regeneron’s Libtayo, and several next-generation antibody and cell therapy platforms have reshaped cancer treatment. Industry commentary continues to identify Merck, Bristol Myers Squibb, Roche, AstraZeneca, Novartis, and Gilead as major players in cancer immunotherapy, while Moderna and BioNTech are pushing mRNA-based therapeutic cancer vaccines toward clinical relevance.

The market is also moving beyond pandemic-era dynamics. BioNTech recently announced major workforce and manufacturing reductions as COVID-19 vaccine demand declined, while redirecting resources toward oncology and mRNA research. This illustrates a broader shift: mRNA platforms remain important, but future value is increasingly expected to come from oncology, combination vaccines, respiratory vaccines, and therapeutic immunology rather than COVID-19 vaccines alone.

Industry Trend — 2026

The vaccine and immunotherapy industry in 2026 is shaped by five major trends: mRNA platform transition, respiratory vaccine competition, oncology immunotherapy expansion, antibody engineering, and global vaccine supply resilience.

First, mRNA platforms are moving from pandemic response toward broader clinical utility. Moderna and BioNTech remain the most visible mRNA-native companies, but larger vaccine players such as GSK and Pfizer also continue to invest in mRNA or mRNA-adjacent vaccine development. GSK’s licensing agreement with CureVac for flu, COVID-19, and avian flu vaccines reflected how traditional vaccine leaders are seeking access to next-generation vaccine platforms.

Second, respiratory vaccines remain a major commercial battleground. Influenza, COVID-19, RSV, pneumococcal disease, and combination respiratory vaccines continue to attract investment because they serve large populations and recurring immunization markets. The most successful developers will combine strong clinical data, manufacturing scale, regulatory execution, and public health access.

Third, cancer immunotherapy continues to expand beyond first-generation checkpoint inhibitors. Combination regimens, bispecific antibodies, antibody-drug conjugate combinations, personalized cancer vaccines, T-cell engagers, and cell therapies are reshaping oncology pipelines. Merck, BMS, Roche, AstraZeneca, Regeneron, Genmab, Gilead, Novartis, BioNTech, and Moderna all remain relevant to this broader immunotherapy transition.

Fourth, antibody engineering remains central to immune-based medicine. Genmab, Regeneron, Roche, Amgen, AstraZeneca, and Johnson & Johnson are among the companies investing in monoclonal antibodies, bispecific antibodies, Fc engineering, and immune-modulating biologics. These platforms are important not only for oncology but also for immunology, rare disease, infectious disease, and inflammatory conditions.

Fifth, vaccine supply resilience remains a strategic issue. The WHO report highlights concentration in both value and volume across vaccine manufacturers, with high-income markets dominated financially by large multinational companies and lower-income volume supply heavily dependent on developing-country vaccine manufacturers. This creates both efficiency and supply-security concerns for governments and health systems.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, organizations considered for this ranking were evaluated based on the following eligibility conditions:

• Operates as a vaccine developer, immunotherapy developer, biotechnology firm, pharmaceutical company, or biologics platform company
• Maintains significant activity in infectious disease vaccines, cancer immunotherapy, therapeutic vaccines, monoclonal antibodies, bispecific antibodies, immune modulation, cell therapy, mRNA, or immune-based therapeutics
• Demonstrates meaningful relevance through approved products, clinical-stage pipelines, vaccine supply, immunotherapy franchises, platform technologies, or strategic public health role
• Maintains scientific or commercial capability in immune biology, antigen design, biologics manufacturing, vaccine production, antibody engineering, or clinical immunotherapy
• Demonstrates institutional credibility through regulatory approvals, clinical trial execution, manufacturing capacity, public health contribution, commercial adoption, or specialist physician uptake

Pure generic manufacturers, diagnostics-only companies, contract research organizations, medical device companies, and preclinical-only firms without meaningful vaccine or immunotherapy platform maturity were generally excluded.

Methodology — Ranking Factors

Organizations included in the ranking were evaluated using a combination of qualitative and structural considerations rather than short-term market capitalization alone. Key factors considered include:

• Strength of vaccine or immunotherapy portfolio
• Scale and reliability of vaccine manufacturing or biologics production
• Leadership in infectious disease prevention, respiratory vaccines, oncology immunotherapy, or immune modulation
• Breadth and quality of clinical pipeline
• Scientific differentiation in mRNA, antibody engineering, cell therapy, cancer vaccines, or immune-based platforms
• Global public health relevance and access capability
• Regulatory execution, clinical evidence, and commercial adoption
• Institutional resilience, platform durability, and long-term strategic relevance

The objective of the ranking is to identify vaccine and immunotherapy developers whose platforms maintain sustained relevance within the global healthcare ecosystem.

The Healthcare Ranking Top 30 Vaccine & Immunotherapy Developers 2026 ranking evaluates organizations based on vaccine leadership, immunotherapy innovation, immune-platform depth, clinical development quality, manufacturing capability, and long-term institutional relevance.

The ranking universe consisted of approximately 130 vaccine and immunotherapy developers globally, from which 30 organizations were selected for inclusion.

Tier classifications reflect relative institutional positioning within the vaccine and immunotherapy developer segment and do not represent clinical recommendations, investment recommendations, or endorsement of any specific vaccine or therapy.

---

Company Profiles and Further Reference

Organization names appearing in this ranking are linked to their corresponding profiles in The Economy Wiki for companies. These profiles provide additional background on each institution, including its principal activities, clinical or commercial focus, market positioning, leadership, corporate information, related rankings, and analysis across The Economy Network.

The Economy Wiki profiles are maintained as editorial reference pages and may be updated as new public information becomes available. A linked profile does not affect ranking eligibility or tier classification.

---

Tier I — Leading Vaccine & Immunotherapy Developers

Merck & Co.

• Headquarters: Rahway, United States
• Founded: 1891

Merck & Co. is one of the most important vaccine and immunotherapy developers globally. The company combines a major preventive vaccine business with one of the most commercially significant oncology immunotherapy franchises in modern medicine.

Merck’s vaccine strength is anchored by major products in HPV prevention, pneumococcal disease, rotavirus, varicella, measles-mumps-rubella, and other infectious disease areas. The company has long been one of the traditional leaders in the high-value global vaccine market, alongside GSK, Sanofi, and Pfizer.

Its immunotherapy strength is even more strategically important. Keytruda has become a defining product in cancer immunotherapy and has reshaped treatment across multiple tumor types. Merck’s oncology platform gives it major relevance in immune checkpoint inhibition, combination regimens, perioperative cancer treatment, and biomarker-driven oncology.

The company’s position is distinctive because it spans both prevention and treatment: vaccines to prevent infectious disease and immunotherapies to treat cancer. Merck’s vaccine heritage, oncology immunotherapy leadership, clinical trial scale, manufacturing capability, and global commercial reach support its position as a Tier I vaccine and immunotherapy developer in 2026.

GSK

• Headquarters: London, United Kingdom
• Founded: 2000

GSK is one of the world’s leading vaccine developers and one of the most institutionally important companies in preventive immunization. Its vaccine business spans shingles, RSV, meningococcal disease, influenza, hepatitis, pediatric vaccines, and other infectious disease categories.

GSK’s strength lies in vaccine science, adjuvant technology, clinical development, manufacturing, and global public health access. The company has long been one of the traditional leaders in global vaccines and continues to invest in next-generation platforms, including mRNA vaccine development through its CureVac agreement.

Beyond vaccines, GSK maintains relevance in immunology and specialty medicine, although its primary position in this category is vaccine leadership. Its respiratory and infectious disease expertise gives it a strong position in markets where prevention, immune response, and public health intersect.

GSK’s broad vaccine portfolio, scientific expertise, adjuvant capabilities, respiratory vaccine strength, and global manufacturing infrastructure support its position as a leading vaccine and immunotherapy developer.

Pfizer

• Headquarters: New York, United States
• Founded: 1849

Pfizer remains one of the most important vaccine developers globally, with major franchises in pneumococcal disease, RSV, COVID-19, and other infectious disease categories. Its partnership with BioNTech established Pfizer as a central player in mRNA vaccine commercialization and demonstrated its ability to rapidly scale global vaccine supply.

Pfizer’s vaccine strength lies in commercial scale, regulatory execution, manufacturing, and global access. The company has been identified among major vaccine manufacturers and remains one of the traditional high-value leaders in the vaccine market.

The company is also relevant in immunotherapy through oncology, though it is less defined by checkpoint immunotherapy than Merck or Bristol Myers Squibb. Its oncology portfolio, including antibody-drug conjugates and targeted cancer medicines following acquisitions, increases its relevance to immune-adjacent and specialty oncology treatment.

Pfizer’s vaccine infrastructure, mRNA commercialization experience, respiratory vaccine presence, global regulatory capability, and large-scale manufacturing support its Tier I position.

Sanofi

• Headquarters: Paris, France
• Founded: 1973

Sanofi is one of the world’s leading vaccine companies and a major participant in immunology. Its vaccine business, historically associated with Sanofi Pasteur, spans influenza, pediatric vaccines, meningococcal disease, travel vaccines, and respiratory disease prevention.

Sanofi’s strength lies in its combination of vaccine manufacturing, public health relevance, and immunology expertise. The company remains one of the traditional global vaccine leaders and is consistently identified among the major vaccine manufacturers worldwide.

Sanofi is also strategically important in immunology through Dupixent, developed with Regeneron, which has become a major immune-modulating biologic across Type 2 inflammatory diseases. While Dupixent is not a vaccine, it reinforces Sanofi’s role in immune-based medicine.

The company’s vaccine scale, influenza and pediatric vaccine portfolio, immunology strength, global access infrastructure, and manufacturing capability support its position among the leading vaccine and immunotherapy developers.

Moderna

• Headquarters: Cambridge, United States
• Founded: 2010

Moderna is one of the most important mRNA platform companies and a leading developer of next-generation vaccines and immunotherapies. The company’s COVID-19 vaccine validated its mRNA platform at global scale, while its future depends on expanding the platform into respiratory vaccines, personalized cancer vaccines, infectious disease, and broader therapeutic applications.

Moderna’s strength lies in its platform orientation. mRNA can be used to encode antigens for vaccines, neoantigens for cancer immunotherapy, and potentially therapeutic proteins in other disease areas. This gives the company relevance across both vaccine development and immune-based therapeutics.

The company remains in a post-pandemic transition, as COVID-19 vaccine demand has normalized. However, its pipeline in RSV, influenza, COVID-flu combinations, and individualized neoantigen therapies gives it continued strategic relevance.

Moderna’s mRNA manufacturing experience, platform depth, respiratory vaccine pipeline, oncology immunotherapy ambition, and global vaccine credibility support its position as a Tier I vaccine and immunotherapy developer.

---

Tier II — Established Vaccine & Immunotherapy Developers

(Alphabetical order)

AstraZeneca

• Headquarters: Cambridge, United Kingdom
• Founded: 1999

AstraZeneca is a major immunotherapy developer with strong relevance in oncology and respiratory medicine. Its oncology portfolio includes immunotherapy, targeted therapies, antibody-drug conjugates, and combination treatment strategies across multiple tumor types.

The company’s immunotherapy relevance is anchored by checkpoint inhibition and broader cancer immunology strategy. AstraZeneca has invested heavily in combination oncology approaches and next-generation treatment platforms, making it one of the important players in cancer immunotherapy beyond the original checkpoint leaders.

AstraZeneca also retains vaccine relevance through its pandemic-era vaccine experience and respiratory disease prevention efforts, although its current strategic weight in this category is stronger in oncology immunotherapy than in broad vaccine manufacturing.

Its oncology platform, immunotherapy development capability, global clinical trial scale, and specialty care focus support its position among established vaccine and immunotherapy developers.

BioNTech

• Headquarters: Mainz, Germany
• Founded: 2008

BioNTech is one of the most important mRNA and immunotherapy companies globally. The company became internationally known through its COVID-19 vaccine partnership with Pfizer, but its foundational scientific identity lies in cancer immunotherapy, individualized cancer vaccines, and mRNA-based immune activation.

BioNTech is currently transitioning away from pandemic-era vaccine dependence toward oncology and immunotherapy. Recent reporting indicates that the company plans to reduce workforce and vaccine manufacturing operations as COVID-19 vaccine demand declines, while redirecting resources toward late-stage oncology drugs and mRNA research.

This transition is strategically important. If BioNTech successfully converts its mRNA platform into approved cancer immunotherapies, it could become one of the most important developers in therapeutic cancer vaccines and immune oncology.

BioNTech’s mRNA platform, global vaccine experience, oncology pipeline, scientific credibility, and immunotherapy orientation support its inclusion among established vaccine and immunotherapy developers.

Bristol Myers Squibb

• Headquarters: Princeton, United States
• Founded: 1887

Bristol Myers Squibb is one of the foundational companies in modern cancer immunotherapy. Its checkpoint inhibitor portfolio, including Opdivo and Yervoy, helped define the immuno-oncology era and continues to play a major role in cancer treatment.

BMS’s strength lies in oncology and hematology depth. Its immunotherapy assets are used across multiple tumor types and in combination regimens, while its hematology portfolio adds relevance in immune-based and cell therapy-adjacent cancer care. Industry commentary continues to identify BMS as one of the major companies in cancer immunotherapy.

The company faces competitive pressure from Merck and newer oncology platforms, but it remains one of the most clinically important immunotherapy developers globally. Its ongoing work in combination therapy, hematologic malignancies, and immune oncology supports long-term relevance.

CSL Seqirus

• Headquarters: Melbourne / King of Prussia
• Founded: 1916 / Seqirus 2015

CSL Seqirus is one of the world’s most important influenza vaccine developers and manufacturers. As part of CSL, the business benefits from biologics manufacturing expertise, global public health relationships, and strong experience in seasonal and pandemic influenza vaccine supply.

Its vaccine relevance lies in a focused but essential category: influenza prevention. Seasonal influenza vaccination remains a recurring public health requirement, while pandemic preparedness depends on manufacturers with scalable vaccine production capacity.

CSL’s broader immunology relevance also includes plasma-derived therapies through CSL Behring, although CSL Seqirus is the vaccine-specific platform. Its role in influenza vaccine supply, public health preparedness, and biologics manufacturing supports its inclusion among established vaccine developers.

Genmab

• Headquarters: Copenhagen, Denmark
• Founded: 1999

Genmab is a leading antibody-based immunotherapy developer with particular strength in oncology. The company has developed antibody platforms that contributed to major cancer medicines and continues to build a pipeline of bispecific antibodies and immune-modulating therapeutics.

Genmab’s strength lies in antibody engineering. Cancer immunotherapy increasingly depends on sophisticated biologics, including monoclonal antibodies, bispecific antibodies, and antibody-based immune engagement. Genmab is one of the most important European biotechnology companies in this field.

Its partnership model has allowed it to create major value while expanding its own commercial and development capabilities. Genmab’s antibody platform, oncology focus, and bispecific pipeline support its position among established immunotherapy developers.

Johnson & Johnson

• Headquarters: New Brunswick, United States
• Founded: 1886

Johnson & Johnson has meaningful relevance across vaccines, immunotherapy, oncology, and immune-mediated disease. Its vaccine profile includes pandemic-era vaccine development and historical infectious disease work, while its strongest current relevance in this category comes from oncology, hematology, immunology, and cell therapy.

J&J’s immunotherapy relevance includes antibody-based oncology treatments, hematologic malignancy therapies, immune modulation, and cell therapy-adjacent platforms. Its broader pharmaceutical business includes immunology and oncology franchises requiring specialist physician engagement and immune biology expertise.

The company’s scale, regulatory experience, manufacturing infrastructure, and global market access support its position as an established vaccine and immunotherapy developer, even though it is not as vaccine-dominant as GSK, Sanofi, Pfizer, or Merck.

Novavax

• Headquarters: Gaithersburg, United States
• Founded: 1987

Novavax is a specialist vaccine developer known for protein-based vaccine technology and adjuvant expertise. The company gained global visibility through its COVID-19 vaccine and continues to pursue respiratory vaccine development, including influenza and combination approaches.

Novavax’s strength lies in its differentiated vaccine technology. Protein-based vaccines can offer an alternative to mRNA and viral vector platforms, particularly for populations or markets seeking more traditional vaccine modalities.

The company has faced commercial and financial challenges, but its vaccine science and adjuvant technology remain relevant. Its inclusion reflects the importance of platform diversity in vaccine development and global immunization strategy.

Regeneron Pharmaceuticals

• Headquarters: Tarrytown, United States
• Founded: 1988

Regeneron is a major immunotherapy and antibody therapeutics developer. The company’s biologics platform has produced important medicines in ophthalmology, immunology, oncology, and rare disease, while its antibody discovery capabilities make it highly relevant to immune-based medicine.

Regeneron’s immunotherapy relevance includes Libtayo in oncology and Dupixent in immune-mediated inflammatory disease, developed with Sanofi. The company’s antibody technology also has applications in infectious disease, rare disease, and inflammatory conditions.

Its strength lies in internal scientific capability and antibody engineering. Regeneron’s discovery engine, biologics manufacturing, and commercial success make it one of the most important immune-based therapeutic developers globally.

Roche

• Headquarters: Basel, Switzerland
• Founded: 1896

Roche is a major immunotherapy developer with deep relevance in oncology, antibody therapeutics, and diagnostics-linked precision medicine. Its oncology portfolio includes immunotherapy, targeted therapies, hematology, and biologics across multiple cancer types.

Roche’s strength lies in integrating therapeutics with diagnostics. Immunotherapy increasingly depends on biomarkers, companion diagnostics, tumor profiling, and patient selection. Roche’s combined pharmaceutical and diagnostics infrastructure gives it a distinctive position in this environment.

Although Roche is not a broad vaccine leader, its immunotherapy platform remains highly important. Its oncology depth, antibody expertise, diagnostics integration, and global development capability support its position among established vaccine and immunotherapy developers.

Serum Institute of India

• Headquarters: Pune, India
• Founded: 1966

Serum Institute of India is one of the most important vaccine manufacturers in the world by volume. Its institutional role is especially important in low- and middle-income countries, where large-scale affordable vaccine supply is essential to immunization programs.

The WHO’s 2025 Global Vaccine Market Report identifies Serum Institute of India as the dominant manufacturer by volume, with roughly twice the volume of the next-largest manufacturer. It also notes that developing-country vaccine manufacturers provide a major share of global vaccine volume, especially for lower-income markets.

Serum Institute’s strength lies in manufacturing scale, cost efficiency, and public health contribution. While it may not match the high-value commercial vaccine portfolios of multinational companies, its role in global vaccine access is structurally important.

Its volume leadership, global immunization role, and manufacturing capacity support its inclusion among established vaccine developers.

---

Tier III — Specialist Vaccine & Immunotherapy Developers

(Alphabetical order)

Arcturus Therapeutics

• Core focus: self-amplifying RNA vaccines and genetic medicines

Arcturus Therapeutics is an established healthcare institution whose principal relevance to this ranking lies in self-amplifying RNA vaccines and genetic medicines. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Arcturus Therapeutics contributes a credible combination of these characteristics.

Arcturus Therapeutics is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Bavarian Nordic

• Core focus: commercial vaccines for infectious disease and preparedness

Bavarian Nordic is an established healthcare institution whose principal relevance to this ranking lies in commercial vaccines for infectious disease and preparedness. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Bavarian Nordic contributes a credible combination of these characteristics.

Bavarian Nordic is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Bharat Biotech

Bharat Biotech is an established healthcare institution whose principal relevance to this ranking lies in vaccine & immunotherapy developers. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Bharat Biotech contributes a credible combination of these characteristics.

Bharat Biotech is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

CanSino Biologics

• Core focus: viral-vector and other vaccine technologies

CanSino Biologics is an established healthcare institution whose principal relevance to this ranking lies in viral-vector and other vaccine technologies. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. CanSino Biologics contributes a credible combination of these characteristics.

CanSino Biologics is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

CureVac

CureVac is an established healthcare institution whose principal relevance to this ranking lies in vaccine & immunotherapy developers. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. CureVac contributes a credible combination of these characteristics.

CureVac is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Dynavax Technologies

• Core focus: adjuvanted vaccines and immune-stimulation technology

Dynavax Technologies is an established healthcare institution whose principal relevance to this ranking lies in adjuvanted vaccines and immune-stimulation technology. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Dynavax Technologies contributes a credible combination of these characteristics.

Dynavax Technologies is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Emergent BioSolutions

• Core focus: preparedness vaccines, antibody therapies and manufacturing

Emergent BioSolutions is an established healthcare institution whose principal relevance to this ranking lies in preparedness vaccines, antibody therapies and manufacturing. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Emergent BioSolutions contributes a credible combination of these characteristics.

Emergent BioSolutions is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Gilead Sciences / Kite Pharma

Gilead Sciences / Kite Pharma is an established healthcare institution whose principal relevance to this ranking lies in vaccine & immunotherapy developers. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Gilead Sciences / Kite Pharma contributes a credible combination of these characteristics.

Gilead Sciences / Kite Pharma is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Inovio Pharmaceuticals

• Core focus: DNA medicines and therapeutic vaccine development

Inovio Pharmaceuticals is an established healthcare institution whose principal relevance to this ranking lies in DNA medicines and therapeutic vaccine development. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Inovio Pharmaceuticals contributes a credible combination of these characteristics.

Inovio Pharmaceuticals is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Novartis

Novartis is an established healthcare institution whose principal relevance to this ranking lies in vaccine & immunotherapy developers. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Novartis contributes a credible combination of these characteristics.

Novartis is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Sinovac Biotech

• Core focus: commercial vaccines across viral and bacterial diseases

Sinovac Biotech is an established healthcare institution whose principal relevance to this ranking lies in commercial vaccines across viral and bacterial diseases. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Sinovac Biotech contributes a credible combination of these characteristics.

Sinovac Biotech is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

SK bioscience

• Core focus: vaccine development, manufacturing and global partnerships

SK bioscience is an established healthcare institution whose principal relevance to this ranking lies in vaccine development, manufacturing and global partnerships. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. SK bioscience contributes a credible combination of these characteristics.

SK bioscience is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Valneva

Valneva is an established healthcare institution whose principal relevance to this ranking lies in vaccine & immunotherapy developers. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Valneva contributes a credible combination of these characteristics.

Valneva is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Vaxcyte

• Core focus: next-generation pneumococcal conjugate vaccines

Vaxcyte is an established healthcare institution whose principal relevance to this ranking lies in next-generation pneumococcal conjugate vaccines. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Vaxcyte contributes a credible combination of these characteristics.

Vaxcyte is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

Walvax Biotechnology

• Core focus: commercial and development-stage vaccines

Walvax Biotechnology is an established healthcare institution whose principal relevance to this ranking lies in commercial and development-stage vaccines. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Walvax Biotechnology contributes a credible combination of these characteristics.

Walvax Biotechnology is placed in Tier III because its category-specific capabilities are meaningful and commercially established, while its overall breadth, market influence, or international reach remains more focused than the institutions placed above it. The classification is intended as an editorial assessment of institutional position rather than a medical, investment, or procurement recommendation.

---

Remarks

Vaccine and immunotherapy developers continue to shape modern healthcare by preventing infectious disease, treating cancer, modulating immune responses, and advancing new biologic and genetic platforms. Their role spans public health, oncology, immunology, pandemic preparedness, respiratory disease prevention, and next-generation immune-based therapeutics.

The organizations recognized in this ranking represent companies whose platforms maintain sustained relevance across preventive vaccines, mRNA platforms, oncology immunotherapy, antibody therapeutics, immune modulation, cell therapy, and global vaccine supply. Tier classification reflects relative institutional positioning within the vaccine and immunotherapy developer sector rather than direct clinical quality rankings.

Tier classification reflects relative vaccine portfolio strength, immunotherapy leadership, platform depth, manufacturing capability, clinical evidence, public health relevance, regulatory execution, and long-term strategic resilience. The ranking does not constitute a medical recommendation, patient referral guidance, investment recommendation, or endorsement of any specific vaccine or therapy.

---

Recognition

Inclusion in the Top 30 Vaccine & Immunotherapy Developers 2026 ranking is an editorial determination of The Economy Rankings and is independent of licensing, advertising, sponsorship, or other commercial participation.

Ranked organizations may factually refer to their inclusion in the ranking in their own communications. When describing the result, institutions should accurately reflect the tier structure and methodology used in the published ranking.

How the ranking should be interpreted

• Tier I represents the Top 5 institutions, and the published order within Tier I reflects the ranking order.
• Tier II represents institutions ranked within the Top 15, following Tier I. Institutions within Tier II are displayed alphabetically; their displayed order should therefore not be interpreted as an individual numerical ranking.
• Tier III represents institutions ranked within the Top 30, following Tiers I and II. Institutions within Tier III are also displayed alphabetically, and their displayed order should not be interpreted as an individual numerical ranking.
• An institution’s tier, rather than its alphabetical position within Tier II or Tier III, should therefore be used when describing its standing.

Referencing the ranking

Depending on the institution’s published tier, appropriate factual descriptions may include:

• Tier I: “Ranked Tier I” or “Ranked among the Top 5”
• Tier II: “Ranked Tier II” or “Ranked among the Top 15”
• Tier III: “Ranked Tier III” or “Ranked among the Top 30”

Organizations should not describe an alphabetical position within Tier II or Tier III as a specific numerical rank.

Use of The Economy Rankings recognition materials

Editorial inclusion in a ranking does NOT by itself grant permission to use The Economy Rankings badges, seals, logos, official recognition graphics, licensed quotations, or other proprietary recognition materials.

Organizations wishing to use official The Economy Rankings recognition materials in corporate websites, marketing materials, investor communications, patient or professional communications, presentations, social media, press releases, or other external communications should refer to the applicable licensing terms and usage policies:

• The Economy Rankings License Structure — available licence levels and permitted recognition uses
  Rankings License Structure | The Economy
• The Economy Rankings License Policy — licensing conditions governing use of The Economy Rankings recognition, marks, and related materials
  The Economy Rankings License Policy | The Economy
• Recognition Use Guide — guidance on permitted wording, presentation, attribution, and use of ranking recognition
  Recognition Use Guide | The Economy

Ranking inclusion remains editorially independent regardless of whether an organization purchases or holds a recognition-materials licence.

Licensing inquiries:
[email protected]